Compare ELUT & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELUT | NOTV |
|---|---|---|
| Founded | 2015 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.3M | 23.0M |
| IPO Year | 2020 | 1997 |
| Metric | ELUT | NOTV |
|---|---|---|
| Price | $0.95 | $0.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $7.00 | $3.00 |
| AVG Volume (30 Days) | ★ 476.9K | 455.6K |
| Earning Date | 03-05-2026 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $21,746,000.00 | ★ $513,024,000.00 |
| Revenue This Year | N/A | $6.49 |
| Revenue Next Year | N/A | $4.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 24.08 | 4.54 |
| 52 Week Low | $0.50 | $0.47 |
| 52 Week High | $3.46 | $4.80 |
| Indicator | ELUT | NOTV |
|---|---|---|
| Relative Strength Index (RSI) | 71.32 | 40.38 |
| Support Level | $0.74 | $0.53 |
| Resistance Level | $0.91 | $0.58 |
| Average True Range (ATR) | 0.09 | 0.04 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 97.43 | 37.58 |
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.